Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
TTY Biopharm Co Ltd banner
T

TTY Biopharm Co Ltd
TPEX:4105

Watchlist Manager
TTY Biopharm Co Ltd
TPEX:4105
Watchlist
Price: 74.4 TWD -1.33% Market Closed
Market Cap: NT$18.5B
Write Note Create Alert Ask AI

Wall St Price Targets

Price Targets Summary
TTY Biopharm Co Ltd

Wall Street analysts forecast TTY Biopharm Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TTY Biopharm Co Ltd is 87.72 TWD with a low forecast of 80.8 TWD and a high forecast of 96.6 TWD.

Lowest Forecast
Wall Street Target
NT$80.8
9% Upside
Average Forecast
Wall Street Target
NT$87.72
18% Upside
Highest Forecast
Wall Street Target
NT$96.6
30% Upside
Lowest Forecast
Price Target
80.8 TWD
9% Upside
Average Forecast
Price Target
87.72 TWD
18% Upside
Highest Forecast
Price Target
96.6 TWD
30% Upside
TTY Biopharm Co Ltd Competitors:
Price Targets

Revenue
Forecast

4% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
4% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next 1 year is 13%.

What are analyst estimates?

Gross Profit
Forecast

3% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss
3% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 3%. The projected CAGR for the next 1 year is 14%.

What are analyst estimates?

Operating Income
Forecast

8% / Year
Past Growth
27% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss
8% / Year
Past Growth
27% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 8%. The projected CAGR for the next 1 year is 27%.

What are analyst estimates?

Pre-Tax Income
Forecast

7% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss
7% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 7%. The projected CAGR for the next 1 year is 14%.

What are analyst estimates?

Net Income
Forecast

9% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss
9% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 9%. The projected CAGR for the next 1 year is 15%.

What are analyst estimates?

Continue Research

Summary
intrinsic value, competitors valuation, and company profile.
DCF Valuation
stock valuation using Discount Cash Flow valuation method.
Relative Valuation
stock valuation using valuation multiples.
Wall St Estimates
price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is TTY Biopharm Co Ltd's stock price target?
Price Target
87.72 TWD

According to Wall Street analysts, the average 1-year price target for TTY Biopharm Co Ltd is 87.72 TWD with a low forecast of 80.8 TWD and a high forecast of 96.6 TWD.

What is the Revenue forecast for TTY Biopharm Co Ltd?
Projected CAGR
13%

Over the last 13 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next 1 year is 13%.

What is the Gross Profit forecast for TTY Biopharm Co Ltd?
Projected CAGR
14%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 3%. The projected CAGR for the next 1 year is 14%.

What is the Operating Income forecast for TTY Biopharm Co Ltd?
Projected CAGR
27%

Over the last 13 years, the compound annual growth rate for Operating Income has been 8%. The projected CAGR for the next 1 year is 27%.

What is the Pre-Tax Income forecast for TTY Biopharm Co Ltd?
Projected CAGR
14%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 7%. The projected CAGR for the next 1 year is 14%.

What is the Net Income forecast for TTY Biopharm Co Ltd?
Projected CAGR
15%

Over the last 13 years, the compound annual growth rate for Net Income has been 9%. The projected CAGR for the next 1 year is 15%.

Back to Top
ALPHA SPREAD
Follow us
Join 350,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett